Technical analysis of Climb Bio, Inc. (CLYM): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
Price Performance
| 1 month | -18.86% |
| 3 months | +23.23% |
| Year-to-date | +252.75% |
| 1 year | +565.57% |
52-Week Range
| 52-week High | $18.33 |
| 52-week Low | $1.54 |
| Avg Volume (90d) | 1.3M |
Technical Indicators
| SMA 50 | $14.24 |
| SMA 200 | $9.16 |
| Beta | -0.20 |
| 30-day Volatility (annualised) | 82.6% |
| Price vs SMA 50 | -0.9% |
| Price vs SMA 200 | +54.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.05 | |
| 2025-11 | $1.89 | -7.8% |
| 2025-12 | $4.00 | +111.6% |
| 2026-01 | $4.47 | +11.7% |
| 2026-02 | $7.15 | +60.0% |
| 2026-03 | $6.85 | -4.2% |
| 2026-04 | $8.88 | +29.6% |
| 2026-05 | $10.96 | +23.4% |
| 2026-06 | $13.04 | +19.0% |
| 2026-07 | $11.90 | -8.7% |
| 2026-08 | $13.73 | +15.4% |
| 2026-09 | $14.11 | +2.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $14.11 |
| Market Cap | $808M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.49 |
| EV / EBITDA | -14.25 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 31.45 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 19.34 |